The estrogen-related receptor alpha (ERRα) is a nuclear receptor that acts primarily as a regulator of metabolic processes, particularly in tissues subjected to high-energy demand. In addition to its control of energy metabolism and mitochondrial biogenesis, ERRα has recently been associated with cancer progression. Notably, increased expression of ERRα has been shown in several cancerous tissues, including breast, ovary and colon. However, additional studies are required to gain insight into the action of ERRα in cancer biology, particularly in non-endocrinerelated cancers. Therefore, using a short hairpin RNA-mediated approach, we investigated whether ERRα is required for the rapid growth of colon cancer cells and to maintain their neoplastic metabolic state. Results show that silencing ERRα significantly impaired colon cancer cell proliferation and colony formation in vitro as well as their in vivo tumorigenic capacity. A pronounced delay in G 1 -to-S cell cycle phase transition was observed in ERRα-depleted cells in association with reduced cyclin-dependent kinase 2 activity and hyperphosphorylated state of the retinoblastoma protein along with disturbed expression of several cell cycle regulators, including p15 and p27. Interestingly, ERRα-depleted HCT116 cells also displayed significant reduction in expression of a large set of key genes to glycolysis, tricarboxylic acid cycle and lipid synthesis. Furthermore, using 14 C isotope tracer analysis, ERRα depletion in colon cancer cells resulted in reduced glucose incorporation and glucose-mediated lipogenesis in these cells. These findings suggest that ERRα coordinates colon cancer cell proliferation and tumorigenic capacity with energy metabolism. Thus, ERRα could represent a promising therapeutic target in colon cancer.
Introduction
Cell metabolism is regulated by multiple mechanisms in order to fulfill the basic needs of the cell. Adequate generation of energy and synthesis of macromolecules are even more important in order to sustain the high proliferation rate of malignant cells. Thus, reprogramming of energy status to the biological capabilities of cancer cells is now recognized as a hallmark of cancer (1) . This is often mediated by oncogenic signaling pathways involving PI3K, HIF, p53 and MYC, which integrate nutrient and energy state signals to control the expression of genes important for concomitant cancer cell proliferation and energy metabolism (2) . There is a growing recognition that these metabolic changes could be exploited for targeted anticancer therapy. Therefore, identifying new regulators of cancer cell metabolism amenable to drugs are needed to impact future therapeutic interventions.
The estrogen-related receptor alpha (ERRα) is a well-known regulator of energy metabolism and mitochondrial biogenesis. Despite its homology with estrogen receptors, ERRα is an orphan nuclear receptor since it is not activated by estrogen-like molecules, while being inhibited by synthetic inverse agonists (3) . Its activity is controlled by the interaction with master regulators of energy metabolism such as peroxisome proliferator-activated receptor gamma coactivator-1 alpha/beta (PGC-1α/β) (4, 5) . Interestingly, ERRα is abundantly expressed in tissues with high-energy demand such as the heart, kidney, intestine, skeletal muscle and brown adipose tissue (6) . Furthermore, mice lacking ERRα are unable to adapt to physiological challenges requiring high energy production such as exposure to cold or cardiac pressure overload (7, 8) . In-depth analyses of genome-wide ERRα binding sites and gene expression datasets have revealed that ERRα binds to the promoters and positively regulates almost all genes involved in the generation of energy and intermediate metabolites (through glycolysis, fatty acid oxidation and glutaminolysis), genes required for functional tricarboxylic acid cycle (TCA) and oxidative phosphorylation as well as genes involved in fatty acid synthesis (4, (9) (10) (11) .
In addition to its participation in the regulation of energy metabolic processes, there is rapidly accumulating evidence for a functional action of ERRα in carcinogenesis. Indeed, high ERRα expression has been reported in breast, ovarian and prostate cancers, correlated with poor prognosis (12) (13) (14) (15) (16) . Furthermore, in non-endocrine-related tissues from colorectal cancer patient cohorts, ERRα gene and protein expression was demonstrated to be significantly upregulated compared with adjacent normal colon, in parallel with either advanced tumor stage (17) or tumor-promoting osteopontin expression (18) . As reviewed recently, ERRα has emerged as a transcriptional metabolic regulator that also promotes many processes associated with cancer development (19, 20) . For instance, cell-based studies have clearly established a positive regulation of breast cancer cell proliferation and migratory potential by ERRα (21) (22) (23) (24) (25) (26) and apparent cross talk between the EGF/HER2 and the PGC-1/ERRα signaling pathways (23, 27, 28) . ERRα is also involved in angiogenesis and response to hypoxia and therefore in growth of solid tumors (29) (30) (31) . Previous studies have focused on the contribution of ERRα as a transcriptional regulator of either energy metabolism or breast cancer cell growth although these two functions of ERRα could very well be interrelated and thus pertinent to colon cancers.
The aim of this study was to characterize the function of ERRα in colon cancer cells. We show that shRNA-mediated knockdown of ERRα markedly reduced colon cancer cell growth and tumorigenicity in nude mice. Cell cycle studies revealed delayed G 1 -S transition as well as modification of the expression and activity of certain cell cycle regulators in ERRα-depleted cells. Furthermore, microarray analysis and quantitative PCR (Q-PCR) confirmation indicate that ERRα deficiency affects lipid metabolism gene expression. Finally, ERRα-knockdown colon cancer cells exhibited lower glucose incorporation and lower lipid synthesis from glucose suggesting that ERRα is required for adequate cell growth, possibly by controlling metabolic resources critical to sustaining cancer cell growth.
Materials and methods

Cell culture
Transformed human embryonic kidney cells (HEK293T) and human colon carcinoma cell lines, HCT116, DLD1 and HT29, were grown in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, 100 U/ml penicillin and 100 μg/ml streptomycin (Wisent, St-Bruno, Canada). All cells were cultured in a 5% CO 2 -humidified atmosphere at 37°C. HCT116 cells are hMLH1-deficient and therefore microsatellite unstable, express wild-type p53, wild-type APC and carry activating K-Ras, pi3kca and β-catenin mutations. DLD1 cells are hMLH1-deficient, express mutated p53 and APC and carry activating K-Ras and pi3kca mutations. HT29 cells are microsatellite stable, express mutated
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p53 and APC and carry activating B-Raf and pi3kca mutations (information from American Type Culture Collection and sequencing).
Lentiviral production and transduction
The lentiviral shRNA expression vector targeting hERRα (NM_004451) and scrambled control (shCTL) were obtained from Sigma-Aldrich (Oakville, Canada). Four shRNAs were tested: shERRα#1 (440), shERRα#3 (865), shERRα#4 (1039) and shERRα#5 (1145). Lentiviruses were produced by cotransfecting the shRNA expression vector and the ViraPower Lentiviral Packaging Mix (Invitrogen) in HEK293T cells. HCT116, DLD1 and HT29 cells were infected with viral suspension containing 5 μg/ml polybrene (Sigma-Aldrich) for 6 h. Two days after infection, cells were selected for puromycin resistance for 48 h (2 μg/ml, Sigma-Aldrich) and used for experiments within a week.
Cell growth and soft-agarose assays
For growth kinetic assays, cells were seeded in six-well plates at a density of 30 000 cells/well, and cell number kinetics were determined using a cell particle counter (Coulter Corporation, Miami, FL). Anchorage-independent growth was evaluated by plating HCT116, DLD1 and HT29 populations at 15 000 cells/ well in complete DMEM containing 0.7% agarose type VII (Sigma-Aldrich) in six-well plates with medium changes twice weekly. After 16 days, colonies were stained with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (EMD Biosciences, Mississauga, Canada) (0.5 mg/ml) for 3 h at 37°C. Images were acquired and the number of colonies determined by ImageJ software (NIH).
In vivo tumorigenesis assay
To assay tumor formation in nude mice, HCT116 cell populations were trypsinized and a total of 2 × 10 6 cells suspended in 100 μl DMEM were injected into the dorsal subcutaneous tissue of 5-week-old female CD1 nu/nu mice (five mice/group) (Charles River, Wilmington, MA). Tumor size was measured by a caliper twice weekly and the volume calculated using the formula 4πR 3 /3. Mice were killed 32 days postinoculation and tumors ≥2.5 mm were excised and weighed. All experimental protocols were approved by our Institutional Ethics Committee for Animal Experimentation.
Cell cycle analysis with flow cytometry HCT116 and HT29 cells were seeded at 150 000 cells/well in six-well plates and synchronized at G 0 /G 1 phase by serum deprivation for 48 h. Cells were released into media containing 10% fetal bovine serum with or without nocodazole (0.5 μg/ml, Sigma-Aldrich) to arrest cell cycle in mitosis, and harvested after 0, 8, 12, 16, 20, 24 and 36 h for HCT116, and after 0, 8, 16, 24, 32 and 48 h for HT29. Cells were fixed in 95% ethanol for 24 h at −20 o C, washed in phosphate-buffered saline and resuspended in a propidium iodide (50 μg/ ml)-ribonuclease A (100 μg/ml) solution for 3 h at 4°C. Cell cycle profiles were determined using a FACS Vantage flow cytometer and the CELL Quest Software (Becton Dickinson, San Jose, CA). Cell cycle distribution was analyzed using ModFit software (Verity Software House, Topsham, ME).
Protein expression and immunoblotting
Cells were lysed in chilled Triton buffer (50 mM Tris-HCl pH 7.5, 1% Triton X-100, 100 mM NaCl, 5 mM ethylenediaminetetraacetic acid) supplemented with protease inhibitors. Proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred onto a polyvinylidene difluoride membrane (GE Healthcare, Buckinghamshire, UK) and incubated with primary antibodies and horseradish peroxidase-coupled secondary antibodies. Detection was performed using the Western Lightning™ Chemiluminescence Reagent Plus kit (PerkinElmer, Woodbridge, Canada). Specific antibodies used were cyclin D1 sc-20044 (1/1000), cyclin E sc-481 (1/1000), E2F4 sc-866 (1/1000), E2F1 sc-22820 (1/1000), p27
Kip1 sc-528 (1/500), cyclin A sc-751 (1/1000), p15
INK4B sc-612 (1/500), cdc25A sc-97 (1/1000) and c-myc sc-764 (1/750) (all from Santa Cruz Biotechnologies, CA); hERRα NLS5402 (1/2000, Novus Biologicals, Canada); pRb 554136 (1/750, Pharmingen, Mississauga, Canada); β-actin MAB1501R (1/5000, Chemicon International, Billerica, MA); and anti-rabbit IgG horseradish peroxidase and anti-mouse IgG horseradish peroxidase (1/5000, GE Healthcare). Protein expression was quantified by densitometry using ImageJ software and normalized to that of actin.
Immunoprecipitation/kinase assay Cells were synchronized by serum deprivation for 48 h before being released into media containing 10% fetal bovine serum and harvested after 0, 2, 4 or 8 h in Triton lysis buffer. Cell lysates (500 μg) were incubated with 5 μl of primary antibody (CDK2 sc-163, Santa Cruz Biotechnologies) for 2 h at 4°C under agitation. Four micrograms of protein A-Sepharose (GE Healthcare) was subsequently added for 1 h at 4°C under agitation. Immunocomplexes were washed three times with ice-cold Triton lysis buffer, rinsed twice in kinase buffer (40 mM Hepes pH 7.4, 20 mM MgCl 2 , 1 mM dithiothreitol and 10 mM p-nitrophenyl phosphate) and incubated for 30 min at 30°C with [γ-32P] adenosine triphosphate (ATP; PerkinElmer) and histone H1 (Sigma-Aldrich) as substrate. Proteins were solubilized in Laemmli's buffer, separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and exposed on film.
RNA extraction and real-time Q-PCR
Total RNA was isolated using the Totally RNA kit (Invitrogen) and treated with deoxyribonuclease I according to the manufacturer's instructions (QIAGEN, Mississauga, Canada) before RNA reverse transcription. Q-PCRs were performed using Brillant® II SYBR Green QPCR master mix in a MX3000P Real-Time System (Stratagene, Cedar Creek, TX). Expression of each gene was calculated by the ΔΔC T method and normalized to β2-microglobulin expression.
Microarray and data analysis
Six probes for microarray analysis were generated from RNA isolated from three independent pools of HCT116 shCTL and HCT116 shERRα#5. Affymetrix GeneChip® Human Gene 1.0 ST arrays were screened at the McGill University and Génome Québec Innovation Center. The gene expression data have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus database (accession number GSE38690, http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE38690). To test for statistically significant changes in signal intensity (P-value ≤0.05; significance analysis of microarrays), compiled data (robust multi-array average analysis) were screened using FlexArray 1.1 (Genome Quebec). Data were also analyzed through the use of ToppGene (http://toppgene.cchmc.org) to generate networks of genes associated with biological functions and/or diseases.
Lactate production, glucose incorporation and lipid synthesis from glucose
Cells were seeded in order to obtain similar confluence; lactate levels relative to total protein in the culture medium were measured 24 h later using a Roche Modular P automated clinical chemistry analyzer (Roche Diagnostics, Laval, Canada). 
Data presentation
Each experiment was conducted at least three times with consistent results. All values in the figures are expressed as mean value ± SD. The data were analyzed using two-tailed Student's t-test. Significance is presented as P-value of <0.05 (*), <0.01 (**) and <0.001 (***); non-significant differences are presented as NS.
Results
Silencing of endogenous ERRα inhibits colon cancer cell growth
To better understand the role of ERRα in colon cancers, its expression was silenced in HCT116, DLD1 and HT29 cell lines using a lentivirus-based shRNA strategy. Figure 1A shows that specific shRNAs knocked down ERRα protein expression by 60-80%, as quantified by densitometry. Moreover, cellular growth was strongly decreased (by approximately 80% at the end of the experiment) in shERRα-expressing HCT116, DLD1 and HT29 cell populations, as compared with parental cells or cells infected with a control shRNA ( Figure 1B-D) . Furthermore, non-cancerous IEC-6 cells stably infected with shERRα#1 (which silences both rat and human ERRα), displayed reduced growth compared with shCTL-infected cells (Supplementary Figure 1A , available at Carcinogenesis Online). These results support an essential contribution of ERRα expression in proliferation and/ or survival of both cancerous and non-cancerous intestinal epithelial cells. Conversely, overexpressing ERRα, with or without its surrogate coactivator PGC-1α, did not increase IEC-6 or HCT116 cell growth (Supplementary Figure 2 , available at Carcinogenesis Online).
ERRα knockdown in colon cancer cells causes a defect in colony formation and in vivo tumorigenesis
We next analyzed the impact of ERRα silencing on anchorageindependent growth of colon cancer cells. Reduction of ERRα expression markedly reduced the ability of HCT116, HT29 and DLD1 cells to form colonies in soft agarose (Figure 2A) . To evaluate the impact of ERRα silencing on the in vivo tumorigenicity of HCT116 cells, HCT116 cells infected with shERRα#4, shERRα#5, shCTL lentiviruses or uninfected cells were subcutaneously implanted into nude mice. As shown in Figure 2B and Supplementary Figure 3 , available at Carcinogenesis Online, the growth rate, volume and final weight of the tumor xenografts formed by shERRα cells were significantly lower than those formed by control cells. In fact, downregulation of ERRα expression reduced the tumorigenic capacity of HCT116 cells since cells infected with shERRα#4 or shERRα#5 formed tumors in only two of five injected mice while every control cell population resulted in tumors ( Figure 2C ). ERRα silencing also strongly reduced in vivo xenograft tumor development in DLD1 cells (data not shown). Therefore, both in vitro and in vivo assays suggest that ERRα expression in colon cancer cells is required to sustain colony and tumor formation.
ERRα silencing delays G 1 -to-S phase transition in colon cancer cells
To determine whether decreased growth of ERRα-depleted cells is caused by a primary defect in cell cycle, cell cycle progression of synchronous HCT116 and HT29 cell populations infected with shCTL or shERRα#5 was first analyzed by flow cytometric assays (fluorescenceactivated cell sorting). As seen in Figure 3A (left panel, −Nocodazole), ERRα-depleted HCT116 cells displayed a marked delay in G 1 -to-S phase transition at 12 and 16 h postrelease from serum deprivation, as compared with control HCT116 cells. Next, to more accurately analyze the transition from G 0 /G 1 to S phase and from S to G 2 /M phase without the overlapping re-entry into the G 0 /G 1 phase, cells were blocked into G 2 /M phase by the addition of nocodazole to serum-containing medium. As illustrated in Figure 3A (right panel, +Nocodazole), silencing of ERRα in HCT116 cells resulted in a 4-to 8-h delay in transit from the G 0 /G 1 to S phase relative to control HCT116 cells such that roughly one-fifth of ERRα knockdown cells were still in G 0 /G 1 phase at 36 h postserum release. These data suggest that ERRα-depleted cells have a delayed transition from G 0 /G 1 to S or alternatively, that a pool of this cell population is unable to exit G 0 /G 1 phase. Interestingly, the G 0 /G 1 to S progression was also delayed in ERRα-silenced HT29 cells, suggesting that ERRα contributes to the transition between these cell cycle phases regardless of p53 and microsatellite status (Supplementary Figure 4 , available at Carcinogenesis Online). Of note, determination of subG 0 population in fluorescence-activated cell sorting profiles and caspase 3 activity (Supplementary Figure 5 , available at Carcinogenesis Online) did not provide evidence for increased apoptosis of colon cancer cells upon shRNA-mediated ERRα repression. Overall, these results suggest that silencing ERRα inhibits the growth of colon cancer cells through a G 1 /S checkpoint arrest.
ERRα silencing affects cell cycle protein expression and activity
To gain better insight into how ERRα regulates G 1 progression and G 1 /S phase transition, the expression and activity of several proteins that control this portion of the cell cycle were analyzed. We first determined the kinase activity of CDK2, a cyclin-dependent kinase required for G 1 /S phase transition. As illustrated in Figure 3B , both basal and seruminduced CDK2 activities were clearly lower in HCT116 cells infected with shERRα#5 than with shCTL. Furthermore, the knockdown of ERRα in HCT116 cells strongly reduced the hyperphosphorylated state of retinoblastoma protein and the expression of several proteins that control G 1 /S phase progression, such as cyclin D1, E2F4, E2F1 and Cdc25A ( Figure 3C ). In addition, ERRα depletion in HCT116 cells modestly reduced cyclin A (~22%) and c-myc (~30%) expression while having no effect on cyclin E levels. Of note, most of these changes were also observed in ERRα-depleted DLD1 and HT29 cells. Finally, expression of cell cycle inhibitors, p27
Kip1 and p15
INK4B
, was consistently increased in all three ERRα-depleted cell lines. Taken together, these results indicate that ERRα deficiency affects the expression profile of cell cycle regulatory proteins, and consequently inhibits the growth of colon cancer cells by arresting the cell cycle at G 0 /G 1 phase.
Transcriptome analyses of HCT116 colon cancer cells upon ERRα depletion
To delineate the genome-wide transcriptional effect of silencing ERRα in HCT116 colon cancer cells, the expression of 28 869 genes was profiled in three populations of control and ERRα-depleted HCT116 cells, 48 h after lentiviral-mediated shRNA expression. Of these, ERRα depletion differentially affected the expression of 1484 genes (P-value <0.01 and fold change >2), including 527 upregulated and 957 downregulated transcripts. Gene ontology analysis of differentially expressed genes revealed many significant clusters associated with cellular bioenergetic metabolic processes, including lipid transport, lipid metabolic processes and small molecule catabolic processes. Among the genes associated with these gene ontology terms, Table I lists selected genes that were significantly up-and downregulated in our microarray analysis of ERRα-silenced HCT116 cells.
ERRα depletion is associated with changes in gene expression involved in glycolysis and lipogenesis
Cancer cells exhibit an altered metabolism characterized by the generation of ATP by glycolysis and of fatty acids by de novo synthesis (33) . The majority of genes involved in these metabolic pathways have been reported to be targets of ERRα (4, (9) (10) (11) 34) . Therefore, the effect of ERRα silencing in HCT116 cells on the expression of a subset of these genes which support the bioenergetic needs of growing cells was further analyzed by Q-PCR. As seen in Figure 4A , knockdown of ERRα in HCT116 cells was associated with lower expression of genes critical for the glycolytic process, such as HK1, G6PC, PFKFB1, PFKFB2, ALDOC, GPT2 and PGM2, likely reducing pyruvate production. However, the fate of pyruvate produced from glycolysis in ERRα-depleted HCT116 cells remained unclear based on the gene expression profile. Indeed, pyruvate is converted to acetyl-CoA by pyruvate dehydrogenase, for which gene expression is unaffected by ERRα depletion. However, pyruvate dehydrogenase is inhibited by a family of pyruvate dehydrogenase kinases 1-4 (33), encoded by genes significantly downregulated by ERRα depletion. This could result in Fig. 3 . ERRα depletion affects G 1 /S transition and cell cycle regulatory proteins in colon cancer cells. (A) HCT116 cells were infected with lentiviruses encoding for a non-targeting shRNA (shCTL) or shERRα#5. Forty-eight hours postinfection, cells were synchronized by serum starvation for 48 h and harvested at the indicated times after release into serum-containing media, in the presence or absence of nocodazole. Propidium iodide-stained cell populations were analyzed for DNA content using flow cytometry. Graphs represent cell counts in y-axis and DNA content in x-axis. Percentages of cells in phases G 0 /G 1 , S and G 2 /M are indicated. Experiments were repeated twice with identical results. (B) HCT116 cell populations were synchronized by serum starvation and assayed for CDK2 kinase activity on histone H1 at 0, 2, 4 and 8 h after release in media containing serum. Phosphorylated histone H1 was visualized by autoradiography after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (upper panel). Equivalent amount of immunoprecipitated CDK2 protein was quantified by western blot with specific antibody against CDK2 (lower panel). (C) HCT116, DLD1 and HT29 cells infected with shCTL of shERRα#5 were harvested 48 h postinfection and cell lysates were submitted to western blot analysis with specific antibodies. In all instances, the membranes were stripped and reprobed with β-actin antibody to confirm equal protein loading, of which a representative blot is shown. 
Genes selected for Q-PCR analysis are given in italics.
preferential conversion of pyruvate into acetyl-CoA instead of lactate in cells knocked down for ERRα. In cancer cells, glycolysis is linked to de novo lipogenesis by the availability of cytosolic acetyl-CoA, which is produced from citrate by ATP citrate lyase (33) . Herein, gene expression of this target enzyme for cancer therapy was strongly reduced in ERRα-depleted HCT116 cells. Furthermore, the expression of other key genes of fatty acid and sterol metabolism, including ACCA and ACCB (acetyl-CoA carboxylase α and β), FASN (fatty acid synthase), SCD1 (stearoyl-coA desaturase-1) and ACSL1 (acetyl-CoA synthase long-chain), was significantly reduced in ERRα-depleted cells. Of note, ERRα depletion also reduced the expression of genes involved in the regulation of glutaminolysis and in the generation of intermediate metabolites from amino acids and glutamate, namely, glutamic pyruvate transaminase (GPT2), aldehyde dehydrogenase 4, member A1 (Aldh4a1) and glutamate oxaloacetate transaminase (Got1). Silencing ERRα in non-cancerous IEC-6 cells also significantly reduced the expression of key metabolic genes (Supplementary Figure 1B , available at Carcinogenesis Online). Altogether and as schematized in Figure 4B , cellular depletion of ERRα alters the expression of genes involved in bioenergetic pathways, such as energy production from glucose, generation of intermediate metabolites and promotion of de novo lipogenesis.
ERRα depletion is associated with reduced glucose uptake and lipid synthesis from glucose
To better characterize the consequence of ERRα knockdown on energy metabolism in colon cancer cells, we first investigated glucose incorporation in HCT116, DLD1 and HT29 cells. In keeping with reduced expression of key genes associated with glycolysis, glucose incorporation was significantly reduced in ERRα-depleted versus control cells ( Figure 5A ). Of note, lactate production was modestly reduced only in ERRα-silenced HT29 cells ( Figure 5B ). Given that aerobic lactate production is preserved in some ERRα-depleted cells in which glucose incorporation, and possibly pyruvate production, is reduced, this lack of substrate could impact anabolic processes such as lipid synthesis. Accordingly, ERRα-depleted cells displayed reduced lipid synthesis from glucose ( Figure 5C ). Collectively, these results suggest that ERRα is required for adequate glucose incorporation and lipid synthesis from glucose in colon cancer cells.
Discussion
ERRα is a regulator of metabolic function that controls multiple biosynthetic pathways involved in energy metabolism. Herein, we provide new insights into the protumorigenic action of ERRα. Using shRNA to silence ERRα expression, we demonstrate that this constitutively active nuclear receptor is required for colon cancer cell growth in vitro and in vivo and for the expression of cell cycle regulatory proteins controlling G 1 /S phase transition. Our data also show that silencing ERRα in colon cancer cells affects the expression of genes involved in bioenergetic functions and reduces glucose incorporation and lipogenesis from glucose. These results are consistent with a growth-promoting action of ERRα in colon cancer and suggest that ERRα contributes to the coordination of energy-generating and biosynthetic pathways to effectively promote colon cancer cell proliferation.
There is increasing evidence supporting a role for ERRα as a protumorigenic factor. In hormone-responsive cancers such as breast cancer, high ERRα expression has been found to correlate with poor clinical outcome and/or unfavorable biomarkers such as ERα negativity and elevated ErbB2 expression (11, 12, 15) . As direct evidence of its protumorigenic action, ERRα deficiency significantly delays tumor formation in a mouse model of ErbB2-induced mammary tumorigenesis (34) . Furthermore, in non-endocrine-related colorectal cancers, ERRα gene expression also parallels advanced tumor stage, suggesting that ERRα participates in cancer progression either by tissue-specific mechanisms or by promoting key processes required for tumor growth. Colorectal cancer evolves through the addition of mutation in tumor suppressors, including APC and p53, and oncogenic activation of intracellular signaling pathways downstream of growth factor receptors (35) . In this study, in spite of their heterogeneous nature, knocking down ERRα expression in HCT116, HT29 or DLD1 colon cancer cells resulted in profound anchorage-dependent and -independent growth retardation, suggesting that ERRα is necessary to sustain their high level of proliferation. Furthermore, very few small tumors developed when ERRα-silenced HCT116 cells were implanted into nude mice. Since ERRα is known to induce vascular endothelial growth factor messenger RNA expression in breast cancer cell lines (31), ERRα depletion may have further effects on tumor development by reducing angiogenesis. Overall, our observations are in keeping with the growth inhibitory impact of reducing ERRα expression or activity in breast, liver and prostate cancer cells (21, 23, 26, 36) . Of note, silencing ERRα reduced the growth of noncancerous intestinal IEC-6 cells, suggesting that ERRα is also required for normal cell growth. This observation is of particular interest since ERRα knockout mice are viable, in spite of intestinal lipid malabsorption, possibly through compensatory mechanisms (37) . In turn, we found that increasing ERRα expression, together with its surrogate coactivator PGC-1α, was not sufficient to impact either HCT116 or IEC-6 cell growth. This finding is in agreement with the observations of Fisher et al. (38) , whereby the expression of constitutively active VP16-ERRα stimulated metabolism but not growth in KSR1 −/− MEFs expressing H-ras V12 .
As commonly observed for factors for which the activity is coupled to the availability of bioenergetic substrates, ERRα is required for colon cancer cell cycle progression and its depletion markedly delays G 1 /S phase transition following serum stimulation. In contrast, silencing ERRα did not result in significant cell death in colon cancer cells, in concordance with breast cancer cells transfected with miR-137 in which ERRα expression is downregulated (26) , but in contrast to HepG2 liver carcinoma treated with an ERRα inverse agonist (36) . G 1 /S phase transition involves a variety of regulatory factors including cyclins (D and E), cyclin-dependent kinases (CDK4/6 and CDK2) and CDK inhibitors (p15 INK4B , p21 Cip1 and p27 Kip1 inhibitors) (39) . In colorectal cancer cells, this transition is frequently activated by aberrant cell-proliferative signaling pathways or inactivation of cell cycle-regulating proteins (40) . Herein, CDK2 activity was found to be weaker in serum-starved and synchronized HCT116 ERRα knockdown cells than in control cells, resulting in reduced phosphorylated retinoblastoma protein and a likely release of E2F factors from phosphorylated retinoblastoma protein during the progression from the G 1 to S phase. In addition, silencing ERRα also decreased E2F4 and E2F1 expression, which could contribute to the observed reduction in proliferation, as these transcription factors are required for S-phase entry into the colon cancer cell cycle (41) . The reduction in CDK2 activity in ERRα knockdown cells could also be due to lower levels of Cdc25A phosphatase, which removes inhibitory phosphorylations on CDK2 (42) . Another mechanism whereby silencing ERRα expression could lead to CDK2 inhibition and G 0 /G 1 arrest would be via the strong induction of p27
INK4B
expression. These CDK inhibitors are frequently downregulated in various tumors, and anticancer agents have been reported to restore p27 Kip1 and/or p15 INK4B expression in colorectal cancer cells (43, 44) . Furthermore, the induction, stabilization or nuclear localization of p27 has been shown to be key in inhibiting cyclin E-CDK2 activity (43, 45, 46) . Of note, knocking down the expression of ERRα markedly reduced the levels of phosphorylated retinoblastoma protein in all three cell lines studied, regardless of their microsatellite, p53, APC, K-Ras, pi3kca and β-catenin mutation status. This effect may be cell type specific since some reports have shown that, in breast cancer cells, antagonizing ERRα activity upregulates p21 expression in a p53-dependent manner (21) , and reducing ERRα expression decreases cyclin E levels in a ERα-dependent manner (26) . Furthermore, ERRα could also be a downstream target of various oncogenic factors in certain cell types, since it has been 14 C]-glucose-derived lipid synthesis was assessed as described in the experimental procedure and normalized to cell number. (A-C) Graphs represent mean ± SD of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
shown that (i) ERRα is required to mediate the increased metabolism and anchorage-independent growth of oncogenic Ras in fibroblasts (38) ; (ii) extracellular signal-regulated kinase 8 interacts with and represses ERRα, possibly by controlling its cellular localization (47); (iii) ERRα is responsive to EGF and ErbB2 signaling pathways (27, 28) ; and finally (iv) PGC-1β expression is controlled by ErbB2, IGF-1 and PI3K signaling pathways in breast cancer cells (23) . This suggests a finely tuned regulation of ERRα activity in response to the availability of energetic substrates. In turn, ERRα interacts with MYC, HIFα and β-catenin in breast cancer cells, contributing to their oncogenic signals and metabolic reprogramming (48) .
The coordination of cell cycle and metabolic circuits is essential to sustain proliferation in cancerous cells. In particular, continuous cell growth requires rapidly available supplies of ATP, simultaneously with the conversion of biosynthetic precursors into building blocks for biomass production (1,2,33) . Furthermore, several transcription factors and oncogenes have been involved in coordinating the induction of a gene expression program that allocates nutrients to provide free energy while fueling the anabolic processes (2, 49) . These observations have raised growing interest in exploiting the metabolic dependencies of cancer cells to target key metabolic enzymes as a selective anticancer strategy (50) . Using gene expression profiling, we found that ERRα deficiency in colon cancer cells significantly affected the expression of gene clusters implicated in a very large set of biological functions, ranging from cellular development and adhesion to lipid metabolism and small molecule catabolic processes. More specifically, our ensuing Q-PRC analysis revealed that ERRα depletion significantly reduced the expression of key genes coding for proteins controlling glycolysis, TCA cycle, oxidative phosphorylation and fatty acid synthesis. The expression of the majority of these selected genes are concordant with a larger list of published ERRα target genes in human breast cancer cells, and in metabolically active mouse tissues, showing ERRα occupancy and/or activation of the promoter of genes encoding enzymes involved in virtually every step of energy and biomass generating pathways (3, 4, (9) (10) (11) .
Reminiscent of that observed in this study in cancer cells, functional studies have elegantly shown that the Drosophila ERR ortholog is required to coordinate developmental growth and cellular proliferation with metabolism (51). Indeed, dERR mutants display decreased expression of genes involved in carbohydrate metabolism and die during larval growth with high sugar but low ATP and triglyceride levels, possibly due to defective conversion of dietary nutrient into biomass. In our three colon cancer cell lines tested, ERRα silencing markedly reduced glucose incorporation and lipid synthesis from glucose, suggesting parallel defects in glycolysis and lipogenesis along with loss of neoplastic proliferative advantage. Interestingly, lactate production in the presence of sufficient oxygen, another hallmark of cancer, was not consistently affected by ERRα depletion in colon cancer cells. Furthermore, the expression of lactate dehydrogenase, an ERRα target (52), was unaffected by ERRα silencing. This may be related to the culture conditions used, in which oxygen, glucose and glutamine levels are not limiting. In these proliferating cells, glycolytic ATP production is high and the main role of the TCA cycle is unlikely to maximize ATP production from pyruvate. Rather, the TCA cycle serves as an important source of biosynthetic precursors, including citrate used for lipid biosynthesis and oxaloacetate and α-ketoglutarate used to generate amino acids (33) . Based on published ERRα regulon and the present Q-PCR analysis of gene expression in colon cancer cells, impaired glucose-mediated lipogenesis in ERRα-depleted cells is likely due to a defect in the gene network regulating energy metabolism and the supply of biosynthetic precursor for lipid synthesis.
The observed requirement of ERRα for glucose-mediated lipogenesis in a context of cancer is also in agreement with metabolic studies showing that ERRα null mice display reduced anabolic pathways such as lipogenesis in adipose tissues, associated with resistance to high-fat diet-induced obesity and altered expression of genes driving lipid, eicosanoid and steroid synthesis (53) . As an orphan nuclear receptor, the ability of ERRα to regulate energy metabolism has been tied to the expression and activity of members of the PGC-1 family of coactivators (3) . In primary adipocyte cultures, ERRα-induced adipogenesis has been shown to be triggered by modulating the expression of PGC-1β (54) . At the present time, the effect of PGC-1α in colorectal cancer remains controversial since a recent study showed that PGC-1α promotes apoptosis in colorectal cancer cells (55) while another demonstrated that loss of PGC-1α protects mice from azoxymethane-induced carcinogenesis by inducing gene expression programs supporting lipogenesis (56) .
Finally, the vast majority of studies showing that ERRα promotes cancer cell growth have been performed in breast cancer-derived cells. Findings from the present study using a powerful loss-offunction strategy suggest that ERRα also promotes the proliferation of colon cancer cells through a gene expression network that facilitates the incorporation of nutrients into cell building blocks, such as glucose-mediated lipogenesis. Such findings provide valuable insight into the biological actions of ERRα and could establish a molecular basis for the development of new cancer therapeutic agents.
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